Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72834 record(s)

Req # A-2021-001487

Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: 000936085, E2B_03628058, E2B_03863854, E2B_03642326, E2B_03853345, E2B_03656279, E2B_04055896, E2B_03644690, E2B_03671794, E2B_03850124, E2B_03839607, E2B_03673968, E2B_03821748.

Organization: Health Canada

169 page(s)
March 2024

Req # A-2021-001520

Adverse Drug Reactions (ADRs). Report numbers: E2B_04568612, E2B_04527571, E2B_04559073.

Organization: Health Canada

103 page(s)
March 2024

Req # A-2021-001750

Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_04446085, E2B_04399700.

Organization: Health Canada

175 page(s)
March 2024

Req # A-2021-001870

Adverse Drug Reactions (ADRs) for PNEUMOVAX 23. Report numbers: E2B_02557027, E2B_02575489, E2B_02576470. ADRs for POSANOL. Report numbers: 000726041, E2B_02412072, E2B_02435616, E2B_02437067, E2B_02248368, 000714601, E2B_02060910.

Organization: Health Canada

144 page(s)
March 2024

Req # A-2021-002091

Adverse Drug Reactions (ADRs). Report numbers: 956643, 956818, 957468, 959483, 960079, 953979, 954435, 955955, 956401, 956812, 958170, 960083, 961290, E2B_04376646, E2B_04369180, E2B_04649779, E2B_04651440, E2B_04668243, E2B_04669463, E2B_04678452.

Organization: Health Canada

120 page(s)
March 2024

Req # A-2022-000062

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: 000979424, E2B_04993704, E2B_05010527, E2B_04988451, E2B_04988450, E2B_05049012, E2B_05077952, E2B_05027959, E2B_05082845, 000979676.

Organization: Health Canada

345 page(s)
March 2024

Req # A-2022-000381

Adverse Drug Reactions (ADRs). Report numbers: E2B_05285073, E2B_05266145, E2B_05222090, E2B_05298555, E2B_05305973, E2B_05290341, E2B_05254658, E2B_05297980, E2B_05226096, E2B_03841771.

Organization: Health Canada

397 page(s)
March 2024

Req # A-2022-000456

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-105622-54.

Organization: Health Canada

84 page(s)
March 2024

Req # A-2022-000570

Adverse Drug Reactions (ADRs). Report numbers: E2B_01232092, E2B_04569236, E2B_04894400, E2B_04456749, E2B_03190583, 000984733, E2B_04993720, E2B_04926588, E2B_05014602, 000978865.

Organization: Health Canada

212 page(s)
March 2024

Req # A-2022-000571

Adverse Drug Reactions (ADRs). Report numbers: E2B_05034900, E2B_04906981, E2B_04922179, E2B_04933182, 000974320, E2B_04877486, E2B_03433916, 000964009, 000973926, 000976615.

Organization: Health Canada

382 page(s)
March 2024
Date modified: